Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 20/20 | 0.67 |
| ▸ | RAMP1 | O60894 | 5/20 | 0.67 |
| ▸ | CALCA | P06881 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3308468 | 0.93 | CALCRL (0.77) | CALCRLRAMP1CALCACYP3A4 | |
| SCHEMBL3308463 | 0.93 | CALCRL (0.77) | CALCRLRAMP1CALCACYP3A4 | |
| SCHEMBL13331894 | 0.91 | CALCRL (0.66) | CALCRLRAMP1CALCACYP3A4 | |
| SCHEMBL13331667 | 0.91 | CALCRL (0.70) | CALCRLRAMP1CALCA | |
| SCHEMBL3311450 | 0.89 | CALCRL (0.67) | CALCRLRAMP1CALCA | |
| SCHEMBL3311444 | 0.89 | CALCRL (0.67) | CALCRLRAMP1CALCA | |
| SCHEMBL3519835 | 0.89 | CALCRL (0.76) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL3519842 | 0.89 | CALCRL (0.76) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL13313742 | 0.88 | CALCRL (0.70) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL13712791 | 0.88 | CALCRL (0.78) | CALCRLRAMP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 84/4885CALCA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.